{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:31:04Z","timestamp":1790487064133,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008673","name":"Yasuda Memorial Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019432","name":"Fujiwara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019432","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.canlet.2011.08.002","type":"journal-article","created":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T23:16:22Z","timestamp":1313622982000},"page":"91-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65 \u2013 a novel Wnt\/\u03b2-catenin signaling inhibitor"],"prefix":"10.1016","volume":"312","author":[{"given":"Rina","family":"Nagao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eishi","family":"Ashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Strovel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayuki","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruriko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyo","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janak","family":"Padia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taira","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2011.08.002_b0005","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2011.08.002_b0010","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia \u2013 advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2011.08.002_b0015","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2011.08.002_b0020","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2011.08.002_b0025","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2011.08.002_b0030","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2011.08.002_b0035","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.08.002_b0040","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Kimura","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.08.002_b0045","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.leukres.2007.11.008","article-title":"Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines","volume":"2","author":"Deguchi","year":"2008","journal-title":"Leuk. Res."},{"key":"10.1016\/j.canlet.2011.08.002_b0050","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1586\/14737140.8.9.1387","article-title":"Abl tyrosine kinase inhibitors for overriding Bcr-Abl\/T315I: from the second to third generation","volume":"8","author":"Tanaka","year":"2008","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"10.1016\/j.canlet.2011.08.002_b0055","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2011.08.002_b0060","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.08.002_b0065","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte\u2013macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2011.08.002_b0070","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2011.08.002_b0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","article-title":"A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib","volume":"115","author":"McWeeney","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.08.002_b0080","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2011.08.002_b0085","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.emboj.7601485","article-title":"Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation","volume":"26","author":"Coluccia","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2011.08.002_b0090","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1158\/1078-0432.CCR-06-2316","article-title":"WNT signaling pathway and stem cell signaling network","volume":"13","author":"Katoh","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.08.002_b0095","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/sj.leu.2404239","article-title":"Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis","volume":"20","author":"Ysebaert","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2011.08.002_b0100","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2008-06-163303","article-title":"Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia","volume":"113","author":"Wu","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.08.002_b0105","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/14622416.7.1.105","article-title":"Expression biomarkers for clinical efficacy and outcome prediction in cancer","volume":"7","author":"Strand","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.canlet.2011.08.002_b0110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2217\/14622416.7.2.227","article-title":"Gene expression profiling in the discovery, optimization and development of novel drugs: one universal screening platform","volume":"7","author":"Bol","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.canlet.2011.08.002_b0115","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1600-0609.2007.00835.x","article-title":"Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn","volume":"78","author":"Ito","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.canlet.2011.08.002_b0120","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.V91.2.641","article-title":"Suppression of cell proliferation and the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-alpha","volume":"91","author":"Yanagisawa","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.08.002_b0125","first-page":"3603","article-title":"Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase","volume":"53","author":"Beran","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.08.002_b0130","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/leu.2008.74","article-title":"Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism","volume":"22","author":"Zhang","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2011.08.002_b0135","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/cdd.2010.6","article-title":"Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment","volume":"17","author":"Takeuchi","year":"2010","journal-title":"Cell Death. Differ."},{"key":"10.1016\/j.canlet.2011.08.002_b0140","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1349-7006.2010.01813.x","article-title":"Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells","volume":"102","author":"Takeuchi","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2011.08.002_b0145","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/cdd.2008.107","article-title":"The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias","volume":"15","author":"Kamitsuji","year":"2008","journal-title":"Cell Death. Differ."},{"key":"10.1016\/j.canlet.2011.08.002_b0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2010.02.008","article-title":"A combination of a DNA\u2013chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro","volume":"294","author":"Kawata","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2011.08.002_b0155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF02983531","article-title":"Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines","volume":"79","author":"Kimura","year":"2004","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.canlet.2011.08.002_b0160","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1158\/1078-0432.CCR-08-1350","article-title":"Beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model","volume":"15","author":"Ashihara","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.08.002_b0165","first-page":"1379","article-title":"Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells","volume":"55","author":"Kimura","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.08.002_b0170","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/stem.5530010205","article-title":"Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis","volume":"1","author":"Kubonishi","year":"1983","journal-title":"Int. J. Cell Cloning"},{"key":"10.1016\/j.canlet.2011.08.002_b0175","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1073\/pnas.0900189106","article-title":"Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation","volume":"106","author":"Abrahamsson","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2011.08.002_b0180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.gde.2006.12.007","article-title":"The many ways of Wnt in cancer","volume":"17","author":"Polakis","year":"2007","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.canlet.2011.08.002_b0185","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1093\/emboj\/16.13.3797","article-title":"Beta-catenin is a target for the ubiquitin\u2013proteasome pathway","volume":"16","author":"Aberle","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2011.08.002_b0190","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ijc.20609","article-title":"Wnt\/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics","volume":"113","author":"Dihlmann","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2011.08.002_b0195","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1535-6108(03)00334-9","article-title":"Small-molecule antagonists of the oncogenic Tcf\/beta-catenin protein complex","volume":"5","author":"Lepourcelet","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2011.08.002_b0200","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1517\/14728222.2011.577418","article-title":"Targeting the Wnt\/beta-catenin signaling pathway in human cancers","volume":"15","author":"Yao","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.canlet.2011.08.002_b0205","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/sj.leu.2404657","article-title":"Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression","volume":"21","author":"Sengupta","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2011.08.002_b0210","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.08.002_b0215","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.08.002_b0220","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3324\/haematol.11369","article-title":"Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation","volume":"92","author":"Nicolini","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2011.08.002_b0225","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood-2009-03-211466","article-title":"Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells","volume":"116","author":"Tanaka","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.08.002_b0230","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2009-01-199307","article-title":"KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR\/ABL translocation,","volume":"114","author":"Shiotsu","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.08.002_b0235","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/j.1349-7006.2008.00810.x","article-title":"Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies","volume":"99","author":"Akahane","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2011.08.002_b0240","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.leu.2404432","article-title":"Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice","volume":"21","author":"Ninomiya","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2011.08.002_b0245","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nbt1350","article-title":"Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region","volume":"25","author":"Ishikawa","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2011.08.002_b0250","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1634\/stemcells.20-4-347","article-title":"Hypoxia modifies proliferation and differentiation of CD34(+) CML cells","volume":"20","author":"Desplat","year":"2002","journal-title":"Stem Cells"},{"key":"10.1016\/j.canlet.2011.08.002_b0255","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/sj.leu.2404224","article-title":"Hypoxia suppresses BCR\/Abl and selects imatinib-insensitive progenitors within clonal CML populations","volume":"20","author":"Giuntoli","year":"2006","journal-title":"Leukemia"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383511004770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383511004770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:29:56Z","timestamp":1759591796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383511004770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0304383511004770"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2011.08.002","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65 \u2013 a novel Wnt\/\u03b2-catenin signaling inhibitor","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2011.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}